CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...
Phase 1, Phase 2
Sevilla, Andalucía, Spain and 23 other locations
in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...
Phase 2
Sevilla, Spain and 9 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Sevilla, Spain and 506 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...
Phase 3
Sevilla, Spain and 508 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Sevilla, Spain and 273 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Sevilla, Spain and 192 other locations
monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]) in second or third line setting in patients with Triple...
Phase 2
Sevilla, Spain and 140 other locations
III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...
Phase 3
Sevilla, Spain and 260 other locations
Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...
Phase 3
Sevilla, Spain and 178 other locations
The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and an...
Phase 1
Sevilla, Andalucia, Spain and 11 other locations
Clinical trials
Research sites
Resources
Legal